Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial-Reference-Cited by-同舟云学术

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial

Published:2014-05 Issue:5 Volume:25 Page:987-991
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fizazi K.,Gravis G.,Flechon A.,Geoffrois L.,Chevreau C.,Laguerre B.,Delva R.,Eymard J.C.,Rolland F.,Houede N.,Laplanche A.,Burcoveanu D.,Culine S.

Funder

Lilly France

Chugai Pharma France

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/5/987/368535/mdu099.pdf

Reference33 articles.

1. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer;Beyer;Ann Oncol,2013

2. EAU guidelines on testicular cancer: 2011 update;Albers;Eur Urol,2011

3. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy;The International Prognostic Factors Study Group;J Clin Oncol,2010

4. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors;Einhorn;N Engl J Med,2007

5. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database;Lorch;J Clin Oncol,2011

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review;International Journal of Gynecologic Cancer;2024-07-11

2. Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors;International Journal of Molecular Sciences;2023-11-28

3. Testicular cancer in 2023: Current status and recent progress;CA: A Cancer Journal for Clinicians;2023-11-10

4. European Association of Urology Guidelines on Testicular Cancer: 2023 Update;European Urology;2023-09

5. French AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer;Progrès en Urologie;2022-11